Oregovomab Phase III Clinical Study fails futility analysis; Data Safety Monitoring Board Recommends Overall Survival Follow Up for Potential Late Immune Effects and Clinical Benefits

Stock Information for Quest PharmaTech Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Quest PharmaTech Inc.

Quest PharmaTech Announces Opposition to OQPBIOM's Acquisition of AdBioTech
Quest PharmaTech Provides Corporate Update
Quest PharmaTech Announces Results from AGM
Quest PharmaTech Announces Filing of 2024 Year End Financial Statements and Restated Fiscal 2023 Financial Statements, and Appointment of New Director
Quest Receives Cash Dividend Payment from OncoQuest
Quest PharmaTech Provides Corporate Update
Quest PharmaTech Announces Results from AGM
Quest PharmaTech Provides Product Development Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.